Critical Elements Lithium Obtains Its First Environmental Authorization to Prepare Rose Lithium-Tantalum Site for Construction
This environmental authorization is the next essential step for site preparation leading to construction of the Project and permits Critical Elements to carry out the activities described below:
stripping of an equipment and materials storage area (in the area of the future pit);
stripping and developing part of the future overburden pile;
stacking of organic matter and overburden on the overburden pile; and
building temporary water management infrastructure.
In accordance with the terms of the environmental authorization received by the Corporation, wetland site preparation activities must begin within two years of the date of issue of the authorization. Furthermore, the Corporation expects to be in a position to commence the activities subject to this authorization once all the conditions mentioned in the Federal and Provincial Project approvals have been met (see news releases of the Corporation dated August 11, 2021, November 2, 2022 and August 14, 2024 for more information relating to these project approvals), the required Project financing has been obtained and a Final Investment Decision is made.
Yves Perron, Vice President of Engineering, Construction and Operations said: 'Today's news represents one of the important steps to allow construction to begin at our Rose Lithium-Tantalum site. To date, we can say that the application process for authorization is well underway. This work will be carried out in compliance with current environmental standards, thus guaranteeing responsible and sustainable management of the Rose Lithium-Tantalum site.'
Qualified Person
Yves Perron, P.Eng., is the Qualified Person who has reviewed and approved the technical content of this press release on behalf of the Corporation.
About Critical Elements Lithium Corporation
Critical Elements aspires to become a large, responsible supplier of lithium to the flourishing electric vehicle and energy storage system industries. To this end, Critical Elements is advancing the wholly-owned, high-purity Rose Lithium-Tantalum project in Québec, the Corporation's first lithium project to be advanced within a land portfolio of over 1,050 km2. On August 29, 2023, the Corporation announced results of a new Feasibility Study on Rose for the production of spodumene concentrate. The after-tax internal rate of return for the Project is estimated at 65.7%, with an estimated after-tax net present value of US$2.2B at an 8% discount rate. In the Corporation's view, Québec is strategically well-positioned for US and EU markets and boasts good infrastructure including a low-cost, low-carbon power grid featuring 94% hydroelectricity. The project has received approval from the Federal Minister of Environment and Climate Change on the recommendation of the Joint Assessment Committee, comprised of representatives from the Impact Assessment Agency of Canada and the Cree Nation Government, received the Certificate of Authorization pursuant to section 164 of Québec's Environment Quality Act from the Québec Minister of the Environment, the Fight against Climate Change, Wildlife and Parks, and the project mining lease from the Québec Minister of Natural Resources and Forests under the Québec Mining Act.
For further information, please contact:
Jean-Sébastien Lavallée
Chief Executive Officer
819-354-5146
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is described in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary statement concerning forward-looking statements
This news release contains 'forward-looking information' within the meaning of Canadian Securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as 'scheduled', 'anticipates', 'expects' or 'does not expect', 'is expected', 'scheduled', 'targeted', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved'. Forward-looking information contained herein include, without limitation, statements relating to expectations regarding Rose project-level activities, notably, (i) completion of the permitting and authorization process, and completion of the work related thereto (ii) securing a strategic partnership and project financing leading to a Final Investment Decision and (iii) respecting the Rose project ramp up and commissioning timeline, expectations regarding potential value creation from ongoing and future exploration activities on the Corporation's projects, and the Corporation's ongoing business plan. Such forward-looking information and statements are based on numerous assumptions, including that general business and economic conditions will not change in a material adverse manner, that fundamentals of lithium / spodumene demand and EV market growth and capacity will continue to be strong, that project financing will be available on reasonable terms, and that governmental and other approvals required to conduct the Company's development activities and planned exploration will be available on reasonable terms and in a timely manner. Although the assumptions made by the Corporation in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.
Although Critical Elements has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking information include, but are not limited to: negative operating cash flow and dependence on third party financing, uncertainty of additional financing, reliance on key management and other personnel, potential downturns in (i) general economic conditions, (ii) demand for lithium / spodumene and (iii) EV market growth, capacity and demand, actual results of exploration activities being different than anticipated, changes in exploration programs based upon results, risks generally associated with the mineral exploration industry, environmental risks, changes in laws and regulations, community relations and delays in obtaining governmental or other approvals, as well as those risk factors set out in the Corporation's Management Discussion and Analysis for its most recent quarter ended November 30, 2024 and other disclosure documents available under the Corporation's SEDAR+ profile (www.sedarplus.ca).
Forward-looking information contained herein is made as of the date of this news release. Although the Corporation has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Fatface to close all US stores and to focus on digital operations
Fashion chain Fatface is set to close all 23 of its stores in the US, transitioning its North American operations entirely to online. Media reports indicate that escalating operational expenses and economic headwinds are the primary reasons for moving away from brick-and-mortar outlets. Fatface CEO Will Crumbie was quoted by Express as saying: "While with any digital migration it can take time, this move will give us additional digital capabilities to enhance the experience for our customers and more seamlessly manage our operations." FatFace operates a network of more than 191 stores in the UK, six in the Republic of Ireland and 20 locations in the US and Canada, alongside a robust social media presence. In 2023, the brand was incorporated into Next. Meanwhile, Fatface is expanding its footprint in the UK market by inaugurating three new stores, renovating seven and refreshing the facades of 28 others during 2025. The B Corp-certified [indicating high social and environmental performance, transparency and accountability standards, verified by the non-profit network B Lab] company also plans to venture into additional international markets via its digital platform soon. In March 2025, FatFace announced that it had improved its B Corp score from 80.4 to 89.1 following a recertification process. "Fatface to close all US stores and to focus on digital operations" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Morgan Stanley Says a New Bull Market Is Underway — Here Are 2 Stocks to Bet on It
Despite recent economic headwinds, a resilient corporate earnings backdrop and better-than-feared data offer some optimism. Still, with July's weak jobs report and signs that inflation may remain stubborn, the big question now is: where will the markets go? Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Watching the situation from Morgan Stanley, chief US equity strategist Mike Wilson is taking an upbeat view. He believes that we're in a bull market – although he describes it as distinct from last year's run. In a recent interview with Bloomberg, Wilson opined: 'We think the bear market ended in basically April. It was a pretty nasty one. There were several along the way, and that was the final flush. And now we're in a new bull market. And capital markets activity is just another sign that that analysis or that conclusion is probably correct… Volatility in bull market or bear market is normal. I mean, you want to see some consolidation… but I want to be very clear, it's still early in the new bull market, so you want to be buying these dips… You have supportive policy, you have positive rate of change, you have good flow dynamics. I mean, those are all the ingredients you need.' With that bullish framework in mind, Morgan Stanley's stock analysts are zeroing in on stocks they believe can thrive in this bull market. We've looked into the data from the TipRanks platform to find out how the Street sees these picks; here's a closer look alongside the Morgan Stanley commentary. Dutch Bros (BROS) The first stock we'll look at is Dutch Bros, the Phoenix-based drive-through coffee chain that was founded as a family-owned pushcart business in Oregon in 1992, opened its first franchise location in 2000, and went public in 2021. The company's expansion started in the Pacific Northwest, but today the company has locations in the Southeast and is extending into the Great Lakes region. The company's menu features a wide range of drinks, from plain coffee to coffee-based specialty drinks to non-coffee favorites such as lemonade or hot chocolate. Dutch Bros also offers a range of seasonal drinks, and basic snacks including muffin tops and granola bars. An app-based rewards program lets customers earn points toward free drinks or place their orders ahead of time for pick-up. The company also offers a gift card program, both digitally and through physical cards. Dutch Bros has proven popular in the years since its founding, and the chain currently boasts 1,043 locations, both franchised and company-owned, across 19 states. The total location count includes 725 that are company-owned and operated, and another 318 that are franchised. Year-over-year, in 2Q25, the location count reflected a 14% increase from 2Q24. The company's network expansion included 113 company-owned stores, and 18 franchise stores. This expansion was reflected in Dutch Bros' quarterly financial results, which showed strong growth YoY and beat the top- and bottom-line forecasts. In the 2Q25 report, the company's revenue grew 28% year-over-year to reach $415.8 million and to beat expectations by $12.2 million. The company's non-GAAP earnings figure, at 26 cents per share, was up 7 cents per share from the prior year and was 8 cents better than had been anticipated. Dutch Bros finished Q2 with $254.4 million in cash and other liquid assets available. For Morgan Stanley analyst Brian Harbour, Dutch Bros' chief attraction is its overall strength. He wrote of the company after the earnings report, 'A strong quarter across the board from BROS continues the recent string of success for the company, and reinforces our prior confidence in the outlook, which we think sets up well into FY26. We'd expect it to support the stock after it has become modestly more debated of late. Both comps and new store productivity came in ahead of expectations again as BROS' sales drivers continue to work in concert, with the food push still ahead. This flowed through to profits, aided by G&A managed well, labor leverage, and some food cost favorability (dairy offsetting coffee), while new unit openings were aligned with our thinking and remain on track for the year.' Looking ahead, Harbour rates BROS as Overweight (i.e., Buy), with a price target of $84 that suggests a one-year upside potential of 24.5%. (To watch Harbour's track record, click here) Overall, BROS has earned a Strong Buy consensus rating from Wall Street's analysts, based on 16 recent reviews that include 15 Buys and 1 Hold. The shares are priced at $67.48 and their average price target, $82.73, implies a gain of 23% by this time next year. (See BROS stock forecast) Globe Life (GL) The second Morgan Stanely pick we'll look at is Globe Life, one of the many firms that together form the backbone of the US insurance industry. Globe Life has been in business since 1900, and today has a market cap of nearly $11.6 billion. While there are much larger firms in the US insurance sector, Globe still has a large footprint – in 2024, the company paid out a total of $1,856,086,935 in claims. The figure included more than $1 billion in life insurance claims, and another $781 million-plus in health insurance claims. Life insurance forms the core of Globe's business; as the company tells its customers, these policies exist to protect families from financial stress at the worst of times. In addition to traditional life insurance policies, the company also offers mortgage protection insurance, designed to protect family homes as well as financial assets. Outside of life insurance, Globe also offers supplemental health insurance policies, including coverage for cancer treatments, critical illnesses, hospital and ICU stays, and accidents. Included in the company's health coverage line-up are Medicare supplemental policies, to back up the coverage offered under the government program. Globe also offers business plans, providing coverage for employees under various life and medical policies. In the past two years, Globe Life has faced headwinds in the form of government investigations – by both the SEC and the DOJ. Both investigations focused on claims of misleading or fraudulent sales practices – but in July of this year, the company announced that both the SEC and the DOJ had closed their cases without taking or recommending enforcement action. The closure of these investigations eased worries about uncertainties toward GL's share performance, and the stock has gained 15% in the last 30 days. Globe Life reported its 2Q25 results last month, and the results were mixed. The company had total revenue of $1.48 billion, for a 3% year-over-year gain – although it missed the forecast by almost $25 million. Globe's bottom line, the net operating income per diluted common share, came in at $3.27, a total that was 2 cents better than the estimates and was up from the figure of $2.97 per share reported for 2Q24. Bob Huang covers this stock for Morgan Stanley, and he sees the easing of investigatory pressures as the key point for Globe Life. 'The multiple contraction last ~18 months was due to DOJ and SEC investigation on sales practices and uncertainties around Health segment earnings. With these headwinds recently removed, we believe the thesis should shift back to fundamentals and steady earnings growth. As such, we believe the relative earnings certainty, and capital light business model should support long term share price appreciation. We see a path for the multiple on Globe Life shares to expand from 9.5x back to the historical 11.0x average,' Huang noted. These comments support Huang's Overweight (i.e., Buy) rating on GL shares, while his $166 price target points toward an upside potential of 19% on the one-year horizon. (To watch Huang's track record, click here) The Strong Buy consensus rating on GL is derived from 10 reviews with a lopsided split of 9 Buys and 1 Hold. The shares are currently trading for $139.05 and the $156.11 average price target indicates a 12% upside potential in the next 12 months. (See GL stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
